A Dose Escalation Study in Solid Tumors and a Dose Expansion Study of PRN1371 in Adult Patients With Metastatic Urothelial Carcinoma

NCT02608125 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

45

Enrollment

INDUSTRY

Sponsor class

Stopped focus portfolio on immune-mediated diseases

Conditions

Solid Tumors
Metastatic Urothelial Carcinoma & Renal Pelvis & Ureter

Interventions

DRUG: PRN1371

Sponsor

Principia Biopharma, a Sanofi Company